{"id":126252,"date":"2026-09-05T07:44:31","date_gmt":"2026-09-05T07:44:31","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/126252\/"},"modified":"2026-09-05T07:44:31","modified_gmt":"2026-09-05T07:44:31","slug":"novartis-rises-as-3-22-billion-deal-targets-faster-drug-delivery","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/126252\/","title":{"rendered":"Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/9064239\/novartis-rises-as-322-billion-deal-targets-faster-drug-delivery?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;GuruFocus&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">GuruFocus<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis (<a href=\"https:\/\/finance.yahoo.com\/quote\/NVS\" data-ylk=\"slk:NYSE%3ANVS;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NYSE:NVS&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"stocks_tp\" rel=\"nofollow noopener\">NYSE:NVS<\/a>), the global pharmaceutical and biotechnology powerhouse, <a href=\"https:\/\/www.reuters.com\/legal\/litigation\/novartis-signs-deal-worth-up-32-billion-alteogens-drug-delivery-technology-2026-09-02\/\" data-ylk=\"slk:slipped;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;slipped&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">slipped<\/a> roughly 0.1% to $161.05 Wednesday despite landing a drug-delivery agreement worth up to $3.22 billion. The deal unlocks Alteogen&#8217;s technology for turning intravenous biologic medicines into faster, under-the-skin injections.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The <a href=\"https:\/\/www.prnewswire.com\/news-releases\/alteogen-enters-option-and-license-agreement-with-novartis-for-development-and-commercialization-of-hybrozyme-enabled-subcutaneous-products-302867513.html\" data-ylk=\"slk:agreement;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;agreement&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">agreement<\/a> covers several potential products powered by Alteogen&#8217;s Hybrozyme platform and ALT-B4 enzyme. But that massive $3.22 billion headline is not an upfront check. Most of the money depends on development, regulatory and commercial milestones being reached.  <\/p>\n<p>    <a href=\"https:\/\/www.gurufocus.com\/stock\/NVS\/summary?search=nvs&amp;r=9e8553cee17e7be6cdee2cf7b0a937b5&amp;r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novartis_rises_as_%243.22_billion_deal_targets_faster_drug_delivery&amp;utm_term=NVS\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery  \u00b7 us.finance.gurufocus         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The prize is simple: cut infusion time, make treatment easier and give key biologics another weapon against more convenient rivals. Yet the stock already trades 23.11% above its GF Value estimate of $130.82, signaling that investors are paying a premium for future execution. Novartis has bought multiple shots at a better delivery modelbut the science and regulators still control the scoreboard.  <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Novartis (NYSE:NVS), the global pharmaceutical and biotechnology powerhouse, slipped roughly 0.1% to&hellip;\n","protected":false},"author":2,"featured_media":126253,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[60731,206],"class_list":["post-126252","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-alteogen","tag-novartis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117217320336695373","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=126252"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126252\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/126253"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=126252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=126252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=126252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}